Compare Badger Meter Inc (BMI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Badger Meter Inc vs Viatris Inc — how do they compare? Badger Meter Inc trades at $135.56 (market cap $3.95B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 4.7× Badger Meter Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BMI | VTRS | |
|---|---|---|
Market Cap | $3.95B | $18.69B |
Sector | Technology | Health |
52-Week High | $193.09 | $17.86 |
52-Week Low | $113.41 | $9.49 |
Enterprise Value | $3.86B | $30.81B |
Dividend Yield | 1.17% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $138.86, up 1.23% today, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. Recent earnings show a Q2 2026 beat but misses in prior quarters, while financials indicate solid profitability with a 14.27% net income margin. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by Business Wire and GlobeNewsWire in early August 2026, though insider buying by a VP in late July signals confidence.
The outlook is mixed: strong fundamentals and analyst upside support growth, but legal risks and earnings volatility pose challenges. Investors may find value if legal concerns resolve, but caution is warranted due to potential sentiment pressure from ongoing litigation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
